Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
influenza virus vaccine, trivalent, cell-based
- Development stage
- Approved
- Lead developer
- CSL Seqirus
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
A **trivalent cell-based influenza virus vaccine** is an inactivated vaccine containing three selected influenza virus antigens grown in mammalian cell culture, not eggs. Its formulation for the 2024-2025 and 2025-2026 US influenza seasons includes: - an A/Wisconsin/67/2022 (H1N1)pdm09-like virus - an A/Massachusetts/18/2022 or A/District of Columbia/27/2023 (H3N2)-like virus - a B/Austria/1359417/2021 (B/Victoria lineage)-like virus Cell-based production is not dependent on eggs; it may yield a vaccine that more closely resembles circulating "wild-type" virus, possibly improving effectiveness over egg-based vaccines. Indicated for **prevention of seasonal influenza** in eligible populations, it works by stimulating neutralizing antibody responses to the three viral strains[5][2][3][4][8].
- Brand names
- Flucelvax Trivalent
- Other names
- trivalent cell-based influenza vaccinecell-culture trivalent influenza vaccine
02
Targets
HA (Hemagglutinin)Neuraminidase
Beyond the preview
Go deeper on influenza virus vaccine, trivalent, cell-based.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on influenza virus vaccine, trivalent, cell-based.